Rockwell Medical (RMTI)
(Delayed Data from NSDQ)
$2.13 USD
+0.03 (1.19%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
RMTI 2.13 +0.03(1.19%)
Will RMTI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RMTI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RMTI
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
RMTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rockwell Medical (RMTI) Increases Despite Market Slip: Here's What You Need to Know
Rockwell Medical (RMTI) Q4 Earnings and Revenues Beat Estimates
Rockwell Medical (RMTI) Rises As Market Takes a Dip: Key Facts
Other News for RMTI
Rockwell Medical to Release Second Quarter 2024 Results on Thursday, August 8, 2024
Rockwell Medical Promotes Tim Chole to Chief Commercial Officer
Rockwell Medical names Tim Chole as Chief Commercial Officer
Analysts Offer Insights on Healthcare Companies: Innovative Eyewear, Inc. (LUCY), Rockwell Med (RMTI) and Mereo Biopharma Group Plc (MREO)
Rockwell Medical: Strong Financial Performance and Strategic Partnerships Justify Buy Rating